E
NovaBay Pharmaceuticals, Inc.
NBY
$0.585
-$0.015-2.50%
E
Sell
1/22/2025Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 1/22/2025 due to an increase in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 1/22/2025 due to an increase in the volatility index and total return index.
E
Sell
1/7/2025Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 1/7/2025 due to a decline in the growth index and volatility index. Operating cash flow declined 256.57% from -$578 to -$2.06M, and EBIT declined 0.76% from -$1.05M to -$1.06M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 1/7/2025 due to a decline in the growth index and volatility index. Operating cash flow declined 256.57% from -$578 to -$2.06M, and EBIT declined 0.76% from -$1.05M to -$1.06M.
E
Sell
10/11/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 10/11/2024 due to an increase in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 10/11/2024 due to an increase in the volatility index.
E
Sell
9/26/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 9/26/2024 due to a substantial decline in the solvency index and volatility index. The quick ratio declined from 0.65 to 0.36.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 9/26/2024 due to a substantial decline in the solvency index and volatility index. The quick ratio declined from 0.65 to 0.36.
E
Sell
8/16/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 8/16/2024 due to an increase in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 8/16/2024 due to an increase in the volatility index.
E
Sell
7/31/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 7/31/2024 due to a decline in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 7/31/2024 due to a decline in the volatility index and total return index.
E
Sell
6/25/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 6/25/2024 due to an increase in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 6/25/2024 due to an increase in the volatility index.
E
Sell
6/7/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 6/7/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.91 to 0.65.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 6/7/2024 due to a decline in the solvency index and volatility index. The quick ratio declined from 0.91 to 0.65.
E
Sell
5/31/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 5/31/2024 due to an increase in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 5/31/2024 due to an increase in the volatility index and total return index.
E
Sell
5/16/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 5/16/2024 due to a decline in the volatility index.
E
Sell
4/29/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 4/29/2024 due to a noticeable increase in the solvency index and volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 4/29/2024 due to a noticeable increase in the solvency index and volatility index.
E
Sell
3/28/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 3/28/2024 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.3745 to -$1.3294, and debt to equity increased from 0.35 to 1.2.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 3/28/2024 due to a major decline in the growth index, solvency index and volatility index. Earnings per share declined from -$0.3745 to -$1.3294, and debt to equity increased from 0.35 to 1.2.
E
Sell
3/25/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 3/25/2024 due to an increase in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 3/25/2024 due to an increase in the volatility index.
E
Sell
3/6/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 3/6/2024 due to a decline in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 3/6/2024 due to a decline in the volatility index.
E
Sell
2/15/2024Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 2/15/2024 due to an increase in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to E+ from E on 2/15/2024 due to an increase in the volatility index.
E
Sell
1/31/2024Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 1/31/2024 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.26 to 0.35, and the quick ratio declined from 1.16 to 0.96.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E from E+ on 1/31/2024 due to a decline in the volatility index, solvency index and total return index. Debt to equity increased from 0.26 to 0.35, and the quick ratio declined from 1.16 to 0.96.
E
Sell
3/14/2023Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 03/14/2023.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 03/14/2023.
D
Sell
2/23/2023Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 2/23/2023 due to an increase in the volatility index and total return index.
E
Sell
2/8/2023Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, volatility index and solvency index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 2/8/2023 due to a decline in the total return index, volatility index and solvency index.
D
Sell
10/4/2022Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 10/4/2022 due to a decline in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 10/4/2022 due to a decline in the total return index.
D
Sell
8/30/2022Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 8/30/2022 due to an increase in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 8/30/2022 due to an increase in the total return index.
D
Sell
8/15/2022Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0022 to -$0.0409, and the quick ratio declined from 1.66 to 1.38.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 8/15/2022 due to a noticeable decline in the growth index, solvency index and valuation index. Earnings per share declined from -$0.0022 to -$0.0409, and the quick ratio declined from 1.66 to 1.38.
D
Sell
5/16/2022Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 5/16/2022 due to an increase in the solvency index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 5/16/2022 due to an increase in the solvency index.
E
Sell
5/13/2022Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/13/2022 due to a decline in the volatility index.
D
Sell
5/4/2022Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 5/4/2022 due to an increase in the total return index.
E
Sell
5/1/2022Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/1/2022 due to a decline in the total return index.
D
Sell
4/21/2022Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 04/21/2022.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 04/21/2022.
E
Sell
4/20/2022Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 4/20/2022 due to a decline in the total return index.
D
Sell
3/31/2022Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 3/31/2022 due to a noticeable increase in the growth index. Earnings per share increased from -$0.051 to -$0.0197, and total revenue increased 43.53% from $1.84M to $2.64M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 3/31/2022 due to a noticeable increase in the growth index. Earnings per share increased from -$0.051 to -$0.0197, and total revenue increased 43.53% from $1.84M to $2.64M.
D
Sell
11/8/2021Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and valuation index. Operating cash flow declined 40.03% from -$1.42M to -$1.99M, EBIT declined 22.3% from -$1.52M to -$1.86M, and earnings per share declined from -$0.0363 to -$0.0437.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 11/8/2021 due to a decline in the growth index, total return index and valuation index. Operating cash flow declined 40.03% from -$1.42M to -$1.99M, EBIT declined 22.3% from -$1.52M to -$1.86M, and earnings per share declined from -$0.0363 to -$0.0437.
D
Sell
11/16/2020Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 11/16/2020 due to an increase in the valuation index, growth index and solvency index. The quick ratio increased from 2.39 to 4.84, debt to equity declined from 1.16 to 0.04, and earnings per share increased from -$0.1475 to -$0.0805.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 11/16/2020 due to an increase in the valuation index, growth index and solvency index. The quick ratio increased from 2.39 to 4.84, debt to equity declined from 1.16 to 0.04, and earnings per share increased from -$0.1475 to -$0.0805.
D
Sell
11/2/2020Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 11/2/2020 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0565 to -$0.1475, and operating cash flow declined 20.35% from -$865 to -$1.04M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 11/2/2020 due to a major decline in the growth index, valuation index and volatility index. Earnings per share declined from -$0.0565 to -$0.1475, and operating cash flow declined 20.35% from -$865 to -$1.04M.
D
Sell
5/8/2020Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 5/8/2020 due to a substantial increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.1262 to -$0.0565, operating cash flow increased 39.47% from -$1.43M to -$865, and EBIT increased 28.47% from -$2.15M to -$1.54M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from D- on 5/8/2020 due to a substantial increase in the growth index, valuation index and total return index. Earnings per share increased from -$0.1262 to -$0.0565, operating cash flow increased 39.47% from -$1.43M to -$865, and EBIT increased 28.47% from -$2.15M to -$1.54M.
D
Sell
4/16/2020Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 4/16/2020 due to an increase in the solvency index, volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 4/16/2020 due to an increase in the solvency index, volatility index and total return index.
E
Sell
3/30/2020Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 3/30/2020 due to a decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.0154 to -$0.1259, debt to equity increased from 1.4 to 3.64, and EBIT declined 38.03% from -$1.71M to -$2.36M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 3/30/2020 due to a decline in the solvency index, valuation index and growth index. Earnings per share declined from -$0.0154 to -$0.1259, debt to equity increased from 1.4 to 3.64, and EBIT declined 38.03% from -$1.71M to -$2.36M.
D
Sell
3/18/2020Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 3/18/2020 due to an increase in the valuation index and volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 3/18/2020 due to an increase in the valuation index and volatility index.
E
Sell
3/3/2020Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 3/3/2020 due to a decline in the volatility index and valuation index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 3/3/2020 due to a decline in the volatility index and valuation index.
D
Sell
2/12/2020Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index, total return index and valuation index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 2/12/2020 due to an increase in the volatility index, total return index and valuation index.
E
Sell
11/12/2019Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 11/12/2019 due to a decline in the total return index, efficiency index and volatility index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 11/12/2019 due to a decline in the total return index, efficiency index and volatility index.
D
Sell
7/11/2019Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 7/11/2019 due to an increase in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D- from E+ on 7/11/2019 due to an increase in the volatility index and total return index.
E
Sell
5/28/2019Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 5/28/2019 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0941 to -$0.25, EBIT declined 152.7% from -$1.61M to -$4.07M, and operating cash flow declined 61.62% from -$1.99M to -$3.22M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D- on 5/28/2019 due to a significant decline in the growth index, solvency index and total return index. Earnings per share declined from -$0.0941 to -$0.25, EBIT declined 152.7% from -$1.61M to -$4.07M, and operating cash flow declined 61.62% from -$1.99M to -$3.22M.
D
Sell
4/1/2019Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 4/1/2019 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 2.36 to 1.74, and total capital declined 18.24% from $6.06M to $4.95M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D- from D on 4/1/2019 due to a decline in the efficiency index, valuation index and solvency index. The quick ratio declined from 2.36 to 1.74, and total capital declined 18.24% from $6.06M to $4.95M.
D
Sell
11/19/2018Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 11/19/2018 due to an increase in the efficiency index and valuation index. Net income increased 3.21% from -$1.59M to -$1.54M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D from E+ on 11/19/2018 due to an increase in the efficiency index and valuation index. Net income increased 3.21% from -$1.59M to -$1.54M.
E
Sell
5/11/2018Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/11/2018 due to a decline in the volatility index, growth index and total return index. EBIT declined 704.08% from $392 to -$2.37M, earnings per share declined from $0.0516 to -$0.14, and total revenue declined 53.34% from $6.32M to $2.95M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to E+ from D on 5/11/2018 due to a decline in the volatility index, growth index and total return index. EBIT declined 704.08% from $392 to -$2.37M, earnings per share declined from $0.0516 to -$0.14, and total revenue declined 53.34% from $6.32M to $2.95M.
D
Sell
11/15/2017Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from D+ on 11/15/2017 due to a noticeable decline in the growth index, efficiency index and total return index. Total capital declined 42.91% from $3.21M to $1.83M, net income declined 40.79% from -$1.74M to -$2.45M, and earnings per share declined from -$0.1135 to -$0.1597.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from D+ on 11/15/2017 due to a noticeable decline in the growth index, efficiency index and total return index. Total capital declined 42.91% from $3.21M to $1.83M, net income declined 40.79% from -$1.74M to -$2.45M, and earnings per share declined from -$0.1135 to -$0.1597.
D
Sell
9/19/2017Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 9/19/2017 due to a major increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.2624 to -$0.1135, net income increased 56.67% from -$4.01M to -$1.74M, and EBIT increased 53.48% from -$3.78M to -$1.76M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 9/19/2017 due to a major increase in the growth index, total return index and efficiency index. Earnings per share increased from -$0.2624 to -$0.1135, net income increased 56.67% from -$4.01M to -$1.74M, and EBIT increased 53.48% from -$3.78M to -$1.76M.
D
Sell
11/11/2016Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from C- on 11/11/2016 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 44.7% from -$2.66M to -$3.85M, and net income declined 38.88% from -$2.69M to -$3.74M.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from C- on 11/11/2016 due to a significant decline in the efficiency index, growth index and valuation index. Operating cash flow declined 44.7% from -$2.66M to -$3.85M, and net income declined 38.88% from -$2.69M to -$3.74M.
C
Hold
11/10/2016Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to C- from D+ on 11/10/2016 due to an increase in the total return index, volatility index and solvency index.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to C- from D+ on 11/10/2016 due to an increase in the total return index, volatility index and solvency index.
D
Sell
8/16/2016Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 8/16/2016 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$1.2425 to -$0.3632, total revenue increased 54.92% from $1.72M to $2.66M, and EBIT increased 52.31% from -$4.62M to -$2.21M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 8/16/2016 due to a large increase in the growth index, total return index and volatility index. Earnings per share increased from -$1.2425 to -$0.3632, total revenue increased 54.92% from $1.72M to $2.66M, and EBIT increased 52.31% from -$4.62M to -$2.21M.
D
Sell
3/11/2016Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from C on 3/11/2016 due to a substantial decline in the volatility index and total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from C on 3/11/2016 due to a substantial decline in the volatility index and total return index.
C
Hold
3/8/2016Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to C from D on 3/8/2016 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 36.25% from $1.2M to $1.64M, EBIT increased 14.92% from -$5.35M to -$6.15M, and operating cash flow increased 8.48% from -$4.14M to -$4.49M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to C from D on 3/8/2016 due to a significant increase in the efficiency index, valuation index and growth index. Total revenue increased 36.25% from $1.2M to $1.64M, EBIT increased 14.92% from -$5.35M to -$6.15M, and operating cash flow increased 8.48% from -$4.14M to -$4.49M.
D
Sell
1/15/2016Downgrade
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from D+ on 1/15/2016 due to a large decline in the total return index.
NovaBay Pharmaceuticals, Inc. (NBY) was downgraded to D from D+ on 1/15/2016 due to a large decline in the total return index.
D
Sell
12/31/2015Upgraded
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 12/31/2015 due to an increase in the growth index. Total revenue increased 19.05% from $1.01M to $1.2M, and EBIT increased 10.06% from -$4.86M to -$5.35M.
NovaBay Pharmaceuticals, Inc. (NBY) was upgraded to D+ from D on 12/31/2015 due to an increase in the growth index. Total revenue increased 19.05% from $1.01M to $1.2M, and EBIT increased 10.06% from -$4.86M to -$5.35M.
AMEX
03/10/2025 12:26PM Eastern
Quotes delayed
